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1682-606X/Copyright ª 2014, TaiwanSummary Cancer-related fatigue (CRF) is a common and crucial disease entity encountered
by oncologists, which has been well defined in the International Classification of Diseases (10th
Revision). However, CRF is under recognized and difficult to treat. Cancer-related fatigue is
frequently associated with advance-staged tumors and cancer therapies such as surgery,
chemotherapy, and radiotherapy. Several studies have evaluated the use of drug interventions
in CRF management but have conflicting results, depending on the population studied and the
outcome measures used. Cancer-related fatigue is apparently associated with systemic inflam-
mation that involves chronic activation/deregulation of the immune system. Traditional Chi-
nese medicine (TCM) approaches may modulate immune functions. Botanical supplements
are used worldwide to enhance immune responses and reduce pathogen-associated symptoms.
This minireview includes an assessment of the efficacy of drug treatment in managing CRF, and
a translational investigation of the anti-CRF activity of TCMs and their isolated components. In
addition, we explored the possible mechanisms of action underlying TCM-mediated effects and
their roles in immunomodulation. Furthermore, TCMs have demonstrated a spectrum of activ-
ities. For instance, TCMs inhibit cyclooxygenase and nitric oxide synthesis, promote free
radical scavenging activity, and reduce inflammatory cytokines. In addition, evidence supports
that TCMs restore impaired T cell functions, improve the M1/M2 macrophage ratio and cytokinere working for either university or hospitals. We claim that we do not have any actual or potential
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174 C.-T. Yeh, L.-S. Wangbalance, inhibit CD4þCD25þ regulatory T (Treg) cells, and suppress chemoradio-resistance in
patients with cancer, which suggest TCMs are promising candidates for the development of
new drug therapies against CRF.
Copyright ª 2014, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.Table 1 Clinical features of cancer-related fatigue.a
The following symptoms have been present every day
or nearly every day during the same 2-week period
in the past month
A Significant fatigue, diminished energy, or increased
need to rest, disproportionate to any recent change
in activity level
Plus  5 of the following:
A Complaints of generalized weakness or limb heaviness
A Diminished concentration or attention
A Decreased motivation or interest in engaging in usual
activates
A Insomnia or hypersomnia
A Experience of sleep as unrefreshing or nonrestorative1. Introduction
Cancer-related fatigue (CRF) is a common health concern
among cancer survivors and patients with cancer; however,
themechanisms underlying the development and persistence
of this symptom remain unclear.1 An overactivation of the
immune system may induce CRF, which is mediated by
proinflammatory cytokines. Several studies have suggested
inflammation has a crucial role in CRF, but data are limited
with virtually no longitudinal data for such patients. We
reviewed the currently available evidence regarding the po-
tential pathophysiological mechanisms that cause CRF and
regarding the management of CRF. The proposed biological
and genetic mechanisms of CRF include cytokine dysregula-
tion, hypothalamicepituitaryeadrenal axis dysfunction, 5-
hydroxytryptophan (5-HT) neurotransmitter dysregulation,
circadian rhythm disruption, alterations in adenosine
triphosphate and muscle metabolism, and vagal afferent
activation.2 In addition, studies have investigated genetic
mechanisms, which include candidate genes, genome-wide
scanning, and gene expression. Furthermore, several behav-
ioral interventions have been evaluated regarding their abil-
ity to reduce CRF among patients with psychosocial risk
factors. Recent data suggest that psychopharmacologic in-
terventions may be effective in the management of CRF.3
Despite these promising findings, no clinical practice guide-
lineshavebeendocumented for theeffectivemanagementof
psychosocial risk factors in CRF. This reviewaims to elaborate
the current understanding of CRF and to provide evidence-
based advice to patients with CRF.
Summary of key points of the minireview:
(1) Cancer-related fatigue is the most common adverse
effect of cancer;
(2) Chronic inflammation is a major mechanism in the
development of cancer-related fatigue;
(3) Host immunology factors increase the risk of fatigue
in patients with cancer; and
(4) Effective interventions against fatigue include TCM
and targeted psychopharmacological treatments.A Perceived need to struggle to overcome inactivity
A Marked emotional reactivity to feeling fatigued
A Difficulty completing daily tasks attributed to feeling
fatigued
A Perceived problems with short-term memory
A Postexertional malaise lasting several hours
a The symptoms cause clinically significant distress or
impairment in social, occupational, or other important areas of
functioning. There is evidence from the history, physical ex-
amination, or laboratory findings that the symptoms are a
consequence of cancer or cancer-related therapy.2. Cancer-related fatigue: an unmet medical
need
Advances in cancer treatment have improved survival rates
and have prolonged the natural history of the disease.
However, the improved survival rates are mitigated by the
adverse effects associated with the therapeutic in-
terventions, thereby resulting in a lower quality of life
(QOL) for cancer survivors. Cancer-related fatigue (CRF) isa very commonly reported symptom with a prevalence rate
of 59e100%, depending on the clinical status of the disease.
Unlike the other types of fatigue caused by noncancerous
factors, CRF is a complex symptom that is not resolved by
resting. Cancer-related fatigue is multifactorial and is
highly prevalent during various cancer treatments such as
surgery and chemoradiotherapy and in patients with
advanced cancers.4 In addition, CRF can develop as a
chronic symptom in disease-free patients and in individuals
who have been successfully treated for cancer. Cancer-
related fatigue confers negative effects on mood, social
relationships, daily activities, and overall QOL in patients
with cancer. Therefore, translational research on CRF is
particularly crucial because of its prevalence and because
available treatments are limited and nonspecific.
Cancer-related fatigue has been recently accepted as a
diagnosis in the International Classification of Diseases 10th
RevisiondClinical Modification. It may be characterized as
a multidimensional phenomenon that develops in patients
with cancer over time, and is associated with diminishing
energy, mental capacity, and psychological condition
(Table 1). According to the revised National Cancer Insti-
tute Common Toxicity Criteria, CRF is associated with
lethargy, malaise, and asthenia. These classifications may
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such a condition.
Despite the high prevalence of CRF, the mechanisms
underlying its onset and persistence among patients with
cancer have not been determined. Few studies have pro-
posed the involvement of various biological mechanisms,
although none of these studies reported a correlation be-
tween the assessed biological parameters (e.g., hemato-
crit, hemoglobin, albumin, and thyroid hormone levels) and
CRF.5 A possible mechanism for the development of CRF is
activation of the immune system in response to the tumor
itself or to the treatments administered for the disease. In
particular, the production of proinflammatory cytokines
such as interleukin (IL)-6 and tumor necrosis factor-alpha
(TNF-a) are part of the host immune response to the
tumor, tissue damage, or depletion of the immune cell
subsets associated with cancer treatment. These cytokines
confer a wide spectrum of peripheral and central effects
that contribute to host defense, which include its effects
on energy consumption.6
Furthermore, several animal studies have demonstrated
that the injection of IL-6, tumor necrosis factor (TNF)-a, or
lipopolysaccharides (which induce IL-1 and TNF-a synthesis)
leads to fatigue, decreased life activity, increased somno-
lence, anorexia, and social withdrawal. These proin-
flammatory cytokines have demonstrated consistent
associations with fatigue levels; however, one study in
which cell supernatant samples were obtained from pa-
tients with early-stage breast cancer reports a significantly
positive association of serum and blood IL-6 levels with the
patients’ fatigue levels during radiotherapy.4 In this longi-
tudinal study, a significant association of serum IL-6 levels
with fatigue levels was observed in patients with terminal
cancer or in older patients (> 50 years) with acute myeloid
leukemia, which suggests that this association is influenced
by the stage and type of cancer. Also, three additional
longitudinal studies report an association of TNF-a with
fatigue in patients receiving cancer treatments. When
stress was induced, higher IL-1 beta (IL-1b) levels wereFigure 1 Cancer-related fatigue: treatreportedly associated with higher fatigue levels in women
with early-stage breast cancer.7
Furthermore, single nucleotide polymorphisms of
inflammation-related genes such as IL-1b (rs16944), IL-6
(rs1800795), IL-6 receptors (rs4129267, rs4845617, and
rs2228145), and C-reactive protein (CRP; rs2794521) exhibit
significant associations with persistent fatigue in aggressive
breast cancer; furthermore, the CRP gene single nucleotide
polymorphism rs3091244 is associated with serum high-
sensitivity CRP levels among patients with advanced breast
cancer and persistent fatigue.8 In addition, Wu et al9 found
that increased fatigue and serum IL-6 levels were higher
among patients with prostate cancer receiving radio-
therapy, although no correlation has been reported be-
tween these parameters. Another study, which was
published in abstract form, reports a correlation between
IL-6 and fatigue in a sample of patients with lung cancer
who received both radiotherapy and chemotherapy. How-
ever, the overall pathogenesis of CRF is not completely
understood. A factor could be the interaction between the
pathological mechanisms of CRF and the mechanisms of
other chronic comorbidities (Fig. 1).3. Inflammation and cancer-related fatigue
An increasing number of studies have explored the role of
proinflammatory cytokines and cytokine networks in the
pathogenesis of CRF. Basic research on neural-immune
signaling in animal models has revealed that peripheral
proinflammatory cytokines activate the central nervous
system (CNS) and exert potent effects on behavioral pro-
cesses such as reduced physical activity, reduced social and
sexual behavior, reduced food and water intake, altered
sleep, increased pain sensitivity and reactivity, and cogni-
tive alterations.10 The basic model that guides this area of
research is that tumors and their treatments can activate
the proinflammatory cytokine network, which leads to the
development of fatigue by affecting the CNS (Fig. 2).able causes and contributing factors.
Figure 2 Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications.
Table 2 Cytokines implicated in cancer-related fatigue
and their main functions.
Cytokine Main function
TNF Fever
Endothelial activation
Neutrophil activation
Migration of dendritic cells to lymph nodes
INF-a Induction of viral resistance
Natural killer cell activation
Macrophage activation
INF-g Macrophage activation
T cell differentiation
IL-1b Fever
HPA axis activation
Lymphocyte activation
Prostanoid activation
Endothelial activation
IL-6 synthesis
IL-4 Inhibits production of TNF and IL-1
Stimulates B cell
IL-6 Fever
Acute-phase protein synthesis
T and B cell differentiation and activation
IL-8 Inflammation
Neutrophil chemotaxis
IL-10 Inhibits inflammation
Inhibits production of IL-1, -6, TNF, and INF-g
HPA Z hypothalamicepituitaryeadrenal; IL Z interleukin;
INF Z interferon; TNF Z tumor necrosis factor.
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association between proinflammatory cytokines and fa-
tigue during radiotherapy, but the studies present mixed
results. An early study conducted in patients with prostate
cancer document an increase in fatigue and in serum IL-1b
levels during radiotherapy, and a more recent study con-
ducted in patients with breast cancer undergoing radio-
therapy reports a positive correlation between fatigue and
serum levels of IL-6 and other inflammatory markers;
however, this association was apparently mediated by the
body mass index.6 Furthermore, other studies have re-
ported a significant correlation between an increase in
fatigue levels and marked changes in the serum cytokines
levels among women receiving radiotherapy for breast or
uterine cancer.4 The tumor itself may be a source of
proinflammatory cytokines during treatment. Cytokines
may be produced in response to tissue damage caused by
radiotherapy or chemotherapy. In patients with newly
diagnosed acute myelogenous leukemia or myeloid
dysplastic syndrome, a correlation was reportedly observed
between the levels of several inflammatory markers and
the symptoms of fatigue.11 In addition, a presurgical eval-
uation of patients with ovarian cancer revealed that pa-
tients with advanced-stage disease exhibited higher IL-6
levels and more severe vegetative symptoms of depression
(including fatigue), compared to patients with early-stage
disease or less malignant tumors.12 By contrast, patients
with advanced cancer exhibited positive intercorrelations
among all inflammatory markers associated with physical
fatigue.
C-reactive protein is an acute-phase protein produced
by hepatocytes on stimulation by IL-6, which indicates a
strong correlation between CRP and IL-6. IL-6 production is
stimulated by IL-1b. Both IL-1b and IL-6 stimulate the
production of IL-1-a, an anti-inflammatory cytokine that
antagonizes IL-1 activity.8 Therefore, IL-6 particularly may
have a crucial role in the fatigue-inducing cytokinecascade. Some studies have revealed an association be-
tween fatigue and IL-1 receptor antagonist or neopterin,
whereas other studies could not determine an association
between these factors. However, the association between
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survivors.7
On the contrary, for inflammation to be considered a
major cause of fatigue in cancer survivors, more inflam-
matory markers should exhibit an association with fatigue
because these markers are not independent and function
through complex and collaborating pathways. A correlation
reportedly exists between depression and physical and
mental fatigue in patients with advanced cancer and in
cancer survivors. In addition, behavioral symptoms such as
depression are hypothetically associated with cytokine
production.
Several recent studies have explored the role of the
immune system in CRF. For more than two decades, studies
have reported several immunological abnormalities in CRF,
although the contribution of these abnormalities in the
pathogenesis of CRF remains unclear.1 Cytokines are in-
flammatory mediators that interact with CRF-related
pathways, which include neurotransmitter metabolism,
neural plasticity, and neuroendocrine functions. Patients
with CRF exhibit high levels of proinflammatory cytokines
such as IL-1, -4, -6, -8, -10, TNF, and interferon-a. Table 2
lists the major cytokines and their respective functions;
appropriate therapeutic interventions could be designed
based on these findings. The diagnostic work-ups and
therapeutic plans of patients with CRF should include the
evaluation of laboratory parameters, pain severity, and
physical performance. These results further substantiate
the multicausality of CRF and the need for large prospec-
tive studies to elucidate the etiological mechanisms.
4. Correlations between chronic inflammation,
tumor-associated macrophages, and cancer-
associated fibroblasts in the tumor
microenvironment
Acute inflammation is a response to any alteration induced
by a pathogen or a physical or chemical insult; its functions
are to eliminate the damage source and to restoreFigure 3 The inflammatory tumor microenvironhomeostasis to the affected tissue.13 However, chronic
inflammation triggers cellular events that can promote a
malignant transformation of cells and carcinogenesis.
Several inflammatory mediators such as TNF-a, IL-6,
transforming growth factor-b (TGF-b), and IL-10, partici-
pate in the development and progression of cancer.
Increasing evidence has proven that inadequately resolved
chronic inflammation may increase the risk of cancer. This
association is evident in several pathological processes such
as endometriosis, chronic prostatitis, chronic gastritis
caused by Helicobacter pylori, and inflammatory bowel
diseases.14
Inflammation can increase the risk of cancer through
bioactive molecules produced by the cells that infiltrate
the tumor microenvironment, and include: (1) cytokines,
growth factors, and chemokines that maintain a sustained
proliferative rate; (2) cell survival signals to avoid
apoptosis; (3) proangiogenic factors; (4) extracellular
matrix-modifying enzymes such as metalloproteinases that
promote epithelialemesenchymal transition; and (5) fac-
tors facilitating other carcinogenesis processes such as
genome instability, reprogramming of energy metabolism,
and immune evasion.14
The inflammatory tumor microenvironment comprises
cancer stromal fibroblasts [e.g., cancer-associated fibro-
blasts (CAFs)], myofibroblasts, mesenchymal stem cells,
tumor-associated macrophages (TAMs), endothelial cells,
leucocytes, and extracellular matrix (i.e., microvascular
endothelial cells) and soluble factors derived from tumor
cells. This inflammatory environment surrounding a tumor
promotes the breakage of the basal membrane, which is
essential for the invasion and migration of metastatic
cells.15 In addition, tumor cells are capable of producing
cytokines and chemokines that facilitate immune system
evasion and aid in the establishment and development of
metastasis (Fig. 3).
Tumor-associated macrophages are a common and
crucial component of chronic inflammation and will be used
as a paradigm of its complexity. Themonocyteemacrophage
lineage cells exhibit considerable plasticity and diversity.ment and its role in promoting tumor growth.
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through various mechanisms: (1) TAMs produce IL-10 and
prostaglandin E2, which suppress antitumor responses; (2)
TAMs release angiogenic factors such as vascular endothelial
growth factor, epidermal growth factor, endothelin-2, and
plasminogen activator that promote tumor growth; and (3)
TAMs facilitate cell invasion metastasis by releasing matrix
metalloproteinases and induce the production of TNF and
the vasodilatation enzyme nitric oxide synthase.16 Further-
more, various murine tumors can exhibit diverse TAM pop-
ulation, which may be partly regulated by hypoxia. Recent
evidence suggests that proliferation can indeed contribute
to macrophage accumulation, particularly during type II
inflammation. M-CSF and IL-4 may regulate the proliferative
capacity of macrophages and include TAMs. Furthermore, in
lung adenocarcinoma, this protumor role of TAMs is further
supported by a clinical study that demonstrated a correla-
tion between increased macrophages in tumor tissue and
poor patient prognosis.17
At least two subpopulations of activated macrophages
coexist in a tumor microenvironment. The first subpopula-
tion is the classically activated macrophages (i.e., M1 mac-
rophages), characterized by the IL-12high, -23high, and -10low
phenotypes; these macrophages can produce TNF-a and
nitric oxide. The M1 macrophages are traditionally regarded
as potent effector cells that can destroy microorganisms and
tumor cells. The other subpopulation is termed alternatively
as “activated macrophages” (i.e., M2 macrophages). Expo-
sure to IL-4, -13, vitamin D3, glucocorticoids, or TGF-b de-
creases the antigen-presenting capability of macrophages
and upregulates the expression of macrophage mannose
receptors (MMR; also known as CD206), scavenger receptors
(SR-A; also known as CD204), CD163, dectin-1, and DC-
SIGN.17 The M2 macrophages are characterized by the IL-
12low, -23low, and -10high phenotypes and are involved in
stromal formation, tissue repair, tumor growth, angiogen-
esis, lymphangiogenesis, and immunosuppression. Whether
TAMs proliferate in human tumors and to what extent remain
to be elucidated. However, the consensus is that M2 TAMs
have an instrumental role in promoting distant metastases
and immune regulation at the primary tumor site.
Furthermore, CAFs have a major role in chronic inflam-
mation; CAFs represent a crucial source of tumor-
promoting cytokines and growth factors and express a
proinflammatory gene signature in skin, breast, and
pancreatic cancers, which is regulated by nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-kB).
The CAFs are believed to originate from mesenchymal stem
cells.18 However, recent data suggest that other bone
marrow cells can also regulate their activity. For instance,
in murine models of breast cancer, endocrinal signals
originating in cancer cells can mobilize Sca þ cKit gran-
ulinþ bone marrow cells. These cells do not directly pro-
mote tumor growth, but they act on the local fibroblasts in
the tumor microenvironment to convert their phenotype
into a cancer-promoting phenotype. The granulin-induced
genes in CAFs include various chemokines, cytokines, and
matrix-remodeling factors that are already implicated in
tumor promotion. In human breast cancer, increased
granulin expression is reportedly correlated with aggres-
sive, triple-negative, basal-like tumor cells, and reduced
patient survival.19 This is another example of cellcooperation in cancer inflammation. A recent paper high-
lighted the importance of fibroblasts in the tumor micro-
environment; on the depletion of fibroblasts that express
fibroblast activation protein-a in tumor-bearing mice, rapid
hypoxic necrosis of the tumor and stromal cells occurred
with IFN-g- and TNF-a-mediated CD8þ T cell cytotoxicity.20
These data suggest that, at least in certain cancers,
TAMs and CAFs contribute to the inflammatory immuno-
suppressive milieu. Other inflammatory cells that have
recently been identified as modifiers of certain inflamma-
tory tumor microenvironments include neutrophils and
mast cells, which are crucial because they release cyto-
kines, chemokines, and reactive oxygen species and pro-
teases. Thus, the underlying cellular networks vary
considerably among different tumors and tumors origi-
nating from different tissues; however, they may share
common mechanisms such as skewing and subversion of
macrophage function suppression.
5. Current treatment of cancer-related fatigue
Cancer-related fatigue is a major clinical concern: well-
controlled CRF can improve the QOL of cancer patients and
their willingness to accept further cancer treatments. How-
ever, CRF is a common symptom that is distressing to patients
and often difficult to treat. Despite the role of drug treat-
ment in CRF management, no consensus has been reached
regarding which drugs are useful. A further understanding of
the recommendations for drug treatment requires knowl-
edge of the classification of recommendations and the levels
of evidence system that have been assigned by the NCCN
guidelines. A review of the study outcomes reveals that
therapeutic drug classes such as methylphenidate or he-
matopoietic agents, corticosteroids, psychostimulants, an-
tidepressants, and L-carnitine may confer beneficial effects
on CRF. These recommendations are based on multiple
clinical trials and are relevant to the size of the population
studied.
5.1. Methylphenidate and hematopoietic agents
Methylphenidate is a psychostimulant and is primarily used
in the treatment of attention deficit-hyperaction disorder
(ADHD); it increases the dopamine levels in the CNS.
Methylphenidate has been used beyond license for various
indications in patients with advanced diseases such as
opioid-induced sedation, depression, and fatigue. Several
control studies and meta-analyses recently investigated the
impact of methylphenidate on CRF.21 The analyses data
support the viewpoint that methylphenidate may be
effective in CRF management. However, these studies were
conducted using a small sample size. In the absence of
convincing results from a single large well-conducted ran-
domized controlled trial, these results must be considered
tentative and provisional. When methylphenidate is used in
patients with CRF, it must only be prescribed under expert
supervision and with active monitoring. Methylphenidate is
one of the few drugs available for treating CRF that have
been supported by clinical trial data. However, further
research is required before recommending its use more
widely. Furthermore, hematopoietics are primarily used to
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which can occur in patients with cancer as a consequence
of disease-related processes or cancer treatment. Twelve
(38% of total) clinical trials tested epoetin alfa (and its
longer-acting counterpart, darbepoetin alfa) against CRF.22
The overall results provide evidence that these drugs
decreased fatigue and improved the QOL in patients with
cancer-related anemia. Furthermore, significant improve-
ments were observed in the energy levels, activity levels,
overall QOL, and fatigue levels.
5.2. Corticosteroids
Corticosteroids, which are hormones produced in the ad-
renal cortex in response to stress and inflammation, are
frequently used to treat pain, nausea, and treat patients
with cancer. Patients with cancer often experience pain
and low energy levels. Three (9% of total) clinical trials,
which include two randomized trials, tested corticosteroids
(e.g., methylprednisolone, prednisone, and megestrol ac-
etate) for treating CRF. The studies revealed that cortico-
steroids improved the cancer-associated symptoms,
particularly pain and fatigue in patients with terminal
cancer. In addition, the adverse effects of long-term
corticosteroid treatments are well-documented. Cortico-
steroids may be helpful in alleviating CRF. In total, 84 pa-
tients were evaluated (dexamethasone, 43 patients;
placebo, 41 patients). The mean ( the standard deviation)
improvement in the FACIT-F subscale on Day 15 was
significantly higher in the dexamethasone group than in the
placebo group. The improvement in the FACIT-F total QOL
scores on Day 15 in the dexamethasone group was signifi-
cantly higher than the scores in the placebo group.
Furthermore, the mean differences in the ESAS physical
distress scores on Day 15 were significantly higher for the
dexamethasone group than for the placebo group. Howev-
er, no significant differences were observed in the ESAS
overall symptom distress or psychological distress scores or
in the incidence of adverse effects. Thus, dexamethasone
was more effective than the placebo in improving CRF and
QOL in patients with advanced cancer.23
5.3. Psychostimulants
Methylphenidate hydrochloride is a CNS psychostimulant. It
blocks the dopamine transporter in the presynaptic cell
membrane, thereby increasing the extracellular dopamine
(D2) levels. It is primarily used in the treatment of attention
deficit-hyperaction disorder (ADHD). Based on the USA Na-
tional Cancer Care Network Guidelines on CRF, psychosti-
mulants must be used for treating CRF only after excluding
the other causes of fatigue. In particular, the effectiveness
of psychostimulants in CRF management remains to be
elucidated. When used at carefully titrated doses, the
incidence of adverse effects due to psychostimulants is low,
and the adverse effects reverse rapidly because of the
drug’s short half-life. Studies have hypothesized that
methylphenidate could be effective in treating CRF
because it produces enhanced alertness, attention, and
vigilance and reduces fatigue in patients with other chronic
conditions such as multiple sclerosis and humanimmunodeficiency virus infection. In these studies (R),
methylphenidate improved fatigue in patients with cancer,
although its effects were not significantly different from
the effects of the placebo in a double-blind study.
Furthermore, dexmethylphenidate is commonly used to
treat attention deficit-hyperaction disorder (ADHD). In a
randomized, placebo-controlled trial of nonanemic pa-
tients with cancer, dexmethylphenidate exhibited signifi-
cantly greater improvements in fatigue during and after
chemotherapy, compared to the placebo.24 Relatively few
randomized, placebo-controlled clinical trials have been
conducted to specifically evaluate the use of psychosti-
mulants in patients with CRF; therefore, the adverse ef-
fects of psychostimulants such as irritability, anorexia,
insomnia, mood fluctuations, nausea, and cardiac
arrhythmia must be considered when making treatment
decisions.25
5.4. Antidepressants
Antidepressants are used to manage depression. Several
patients with cancer experience depression. Among the
evaluated studies, 50% met the inclusion criteria, but only
31% (7104 participants) were deemed suitable for detailed
analysis because they explored fatigue in sufficient detail.
These studies had mixed results with certain drugsdmostly
drugs that stimulate red blood cell production or improve
concentration levelsdthat showed a beneficial effect on
fatigue. Methylphenidate, a psychostimulant drug that im-
proves concentration, is effective for treating CRF; how-
ever, because of the small samples used in the available
studies, further research is required to confirm its role.
Erythropoietin and darbepoetin are drugs that improve
anemia and are effective in CRF management. However,
safety concerns and adverse effects caused by these drugs
prohibit their use for treating CRF. Two (6% of total) recent
clinical trials examined the use of the antidepressant
bupropion sustained release (SR) in CRF management.
Bupropion (Wellbutrin-SR) is used to treat chronic fatigue
syndrome and fatigue associated with multiple sclerosis.
Bupropion SR was associated with an improvement in fa-
tigue scores within 2e4 weeks after treatment initiation.
Further placebo-controlled studies are warranted to
establish the efficacy of bupropion (Wellbutrin-SR) in CRF.
Two (6% of total) double-blinded, placebo-controlled ran-
domized trials report that the newer antidepressant par-
oxetine (Paxil), a selective serotonin reuptake inhibitor,
improves depression but has no effect on fatigue in patients
receiving chemotherapy, which suggests that the underly-
ing causal mechanisms for depression and CRF are distinct.
5.5. L-Carnitine
L-Carnitine is used to manage the adverse effects of
chemotherapy. Chemotherapy often causes anemia and
nausea and depletes the body of carnitine, a crucial protein
derived from an amino acid that is in nearly all cells of the
body. L-Carnitine is one of two forms of carnitine. Three (9%
of total) clinical trials tested L-carnitine for treating CRF. L-
Carnitine, which is commonly used as an energy nutrient, is
administered to patients who do not produce adequate
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Three hundred and thirty-two assessable patients with
cancer-related anorexia/cachexia syndrome were randomly
assigned to one of five treatment arms: (1) medrox-
yprogesterone (500 mg/d) or megestrol acetate (320 mg/d);
(2) oral supplementation with eicosapentaenoic acid (EPA);
(3) L-carnitine (4 g/d); (4) thalidomide (200 mg/d); or (5) a
combination of the aforementioned treatments. Treatment
with L-carnitine significantly improved fatigue. Modafinil is a
mood-brightening and memory-enhancing psychostimulant
that improves wakefulness and is used to treat narcolepsy,
residual sleepiness in people treated for obstructive sleep
apnea, and sleepiness in shift work sleep disorder. Two (6% of
total) clinical trials tested modafinil (Provigil) for treating
CRF.26 Short-term clinical studies have shown improved
wakefulness in patients with other conditions such as mul-
tiple sclerosis, major depression, and Parkinson’s disease.
5.6. Traditional Chinese medicine
Ten trials that included 751 patients with CRF were identi-
fied, but the methodological quality of the trials was gener-
ally poor. Based on the results of a single trial, TCMs used
alone or in combination with chemotherapy or supportive
care exhibited a significant improvement in CRF, compared
to treatment by a placebo, chemotherapy, or supportive
care.27 These TCMs may comprise ingredients such as
Astragalus membranaceus, Radix Codonopsitis Pilosulae,
Radix Ginseng, Radix Glycyrrhizae, Rhizoma Atractylodis
Macrocephalae, Radix Angelicae Sinensis, Rhizoma Cimici-
fugae, Radix Bupleuri, Pericarpium Citri.27 Traditional Chi-
nese medicines used with chemotherapy or supportive care
exhibited superior performance in improving QOL, compared
to chemotherapy or supportive care alone. One trial
demonstrated that TCMs exerted a greater beneficial effect
on relieving anxiety, but exhibited similar effects in allevi-
ating depression. Seven trials reported adverse events, and
no severe adverse effects were reported for patients
receiving TCMs. The findings from a limited number of trials
deem TCMs as effective and safe in CRF management. How-
ever, the current evidence is insufficient to draw a definitive
conclusion because of the poormethodological quality of the
evaluated trials. Thus, rigorously designed trials are war-
ranted to evaluate potential TCMs.6. Targeting cancer-related inflammation:
immune modulators and traditional Chinese
medicine for the treatment of CRF
The field of Traditional Chinese Medicine recognizes CRF as a
deficiency pattern, which is primarily caused by deficiency
of both qi and blood and disharmony of yin and yang and
blood stasis. Traditional Chinese medicines have potential
beneficial effects in treating cancer, suppressing cancer
progression, improving the immune system, and amelio-
rating chemotherapy-induced or radiotherapy-induced
complications and adverse effects such as pain and fa-
tigue. Furthermore, increasing evidence suggests that
certain TCMs such as Coptis chinensis (Huang lian), Scutel-
laria baicalensis (Huang qin), Camellia sinensis (Lu cha),Wedelia chinensis (Peng qi ju), and Songyou Yin (a Chinese
herbal compound), contain abundant phytochemicals, and
may reverse the epithelialemesenchymal transition and
reduce metastasis. Thus, these herbs may be useful as
complementary and alternative treatments and/or as
adjuvant therapy for conventional cytotoxic therapies.
A.membranaceus (Leguminosae) is a verywell-knownand
widely used herbal medicine in China. The dried root of A.
membranaceus has a long history of medical use. It is tradi-
tionally prepared as a tonic that can improve the functioning
of the lungs, adrenal glands, and gastrointestinal tract; in-
crease metabolism; promote healing; and reduce fatigue.
The active pharmacological constituents of A. mem-
branaceus include polysaccharides, saponins, flavonoids, L-
arginine, and L-canavanine. Astragalus polysaccharides
(APS), the primary active extract from A. membranaceus,
exert diverse biological effects through regulating immune
responses such as cellular and humoral immunity, nonspecific
immune functions, and cytokine production. It reduced cell
accumulation, swelling, and the arthritic index of the joints
and serum levels of inflammatory mediators in adjuvant
arthritic rats. The in vivo injection of A. membranaceus
suppresses the proliferation and differentiation of autor-
eactive T-cells by elevating Treg IL-10 and reducing IL-6.
Astragalus polysaccharides regulate the effects of Thl/Th2
imbalance and secreted cytokines as well as promote the
phenotypic and functional maturation of dendritic cells. In
addition to their immunomodulatory and hypoglycemic ac-
tivities, several studies have revealed that APS can be used
for treating inflammatory diseases such as intestinal inflam-
mation and for inhibiting tumor growth and metastasis in
nude mice with cancer cell xenografts. Astragalus poly-
saccharides interestingly reverse multidrug resistance and
inhibit P-gp expression in the colon.28 The combination of
APS with conventional Western medicine has clinically been
shown to prolong survival in patients with lung cancer.
Some more recent studies have investigated the efficacy
of A. membranaceus as a complementary and palliative
medicine for treating CRF. PG2 significantly improved CRF
in the NS-primed group. In the initial 4-week cycle, APS
injection exhibited a higher fatigue-improvement response
rate than that observed with NS alone. In addition,
approximately 82% of the patients who reported improved
fatigue symptoms after the first APS cycle experienced
sustained benefits after the second treatment cycle. Among
the patients treated with APS who did not report any
improvement in their symptoms throughout the first treat-
ment cycle, approximately 71% of the patients reported a
significant improvement in their symptoms after the second
treatment cycle. No major or irreversible toxicities were
observed with APS treatment. Thus, APS may be an effec-
tive and safe treatment for CRF among patients with
advanced cancer.29
Tumor metastasis is the primary cause of cancer-
related mortality. The inflammatory cells in the tumor
microenvironment have a crucial role in tumor growth,
progression, and metastasis. Within the tumor stroma,
TAMs constitute a pivotal class of inflammatory cells, and
compelling evidence suggests that TAMs have a promoting
role in various processes such as carcinogenesis, tumor
growth, angiogenesis, and lymphangiogenesis, and TAMs
are the key regulators of the metastatic phenotype of
Figure 4 A schematic and study highlights of traditional Chinese medicine (TCM) effects on the tumor microenvironment. TCM
inhibits tumor growth and metastasis by blocking NF-kB-dependent proinflammatory cytokine production in tumor-associated
macrophages. Because the proinflammatory cytokine is abundant in the tumor microenvironment and produced from different
types of cells. Based on the hypothesis, TCM seems to have pleiotropic roles in the tumor microenvironment, whereas our literature
demonstrates its role against macrophagic proinflammatory cytokine production in metastatic cancer microenvironment.
Cancer-related fatigue and current management 181cancer cells.17 Tumor-associated macrophages regulate
cancer progression and metastases in the tumor micro-
environment. Furthermore, TAMs are a crucial component
of the leukocyte infiltrate. Tumor-associated macrophage
infiltrates are correlated with tumor progression and poor
prognosis in patients with lung cancer. In breast cancer,
macrophage infiltration is correlated with a poor prog-
nosis. Metastatic breast cancer exhibits poor prognosis
with severe mortality, and the available therapeutic op-
tions remain limited. In addition, numerous studies have
indicated that cancer-related inflammation promotes the
development of tumors. Certain proinflammatory cyto-
kines such as IL-8, -6, and TNF-a activate epi-
thelialemesenchymal transition and eventually facilitate
cell invasion and metastasis.14 However, the activated
phenotype and polarization status of TAMs in solid tumors
are not completely understood, and the anticancer
mechanism of APS and their involvement in the reversal of
TAMs remain unclear. Woo et al30 demonstrated that KSG-
002, a new herbal composition of the radices A. mem-
branaceus and Angelica gigas, suppresses breast cancer by
inhibiting TAM recruitment. KSG-002 furthermore
decreased the infiltrated macrophage numbers in xeno-
graft tumor cohorts, inhibited cell proliferation and
migration, and reduced TNF-a production by inhibiting the
NF-kB pathway. Based on these findings, we conclude that
TCMs can suppress CRF by targeting cancer-related
inflammation and inhibiting TAMs.
7. Conclusion
Cancer-related fatigue is the most common and crucial
posttreatment concern among patients with cancer. It is
not resolved by resting. Increasing evidence has suggestedthat activation of the immune system has a critical role in
CRF. The outcomes of current managements for CRF are
controversial and limited. In addition to conventional
managements for CRF, this minireview suggests that TCMs
or botanical immune modulators may be effective and safe
in CRF management. However, owing to poor and varying
methodological quality of these trials and the heteroge-
neity of TCM intervention, the potential of these findings
must be cautiously interpreted. Our study highlights that
TCMs provide protection against metastasis in the tumor
microenvironment by targeting cancer-associated M2
macrophage activation (Fig. 4); this may have major im-
plications in our understanding of the efficacy of TCMs and
in the discovery of promising therapeutic approaches for
treating lung cancer. However, further rigorous randomized
clinical trials are warranted to overcome the limitations of
the current trials and to increase the strength of the
available evidence.References
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